Your browser is no longer supported. Please, upgrade your browser.
Settings
PPHM Peregrine Pharmaceuticals, Inc. daily Stock Chart
PPHM [NASD]
Peregrine Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own0.20% Shs Outstand43.94M Perf Week-1.90%
Market Cap135.77M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float37.26M Perf Month-4.33%
Income-23.40M PEG- EPS next Q-0.08 Inst Own15.00% Short Float1.37% Perf Quarter-22.56%
Sales79.10M P/S1.72 EPS this Y54.60% Inst Trans16.12% Short Ratio1.72 Perf Half Y-38.36%
Book/sh1.25 P/B2.47 EPS next Y- ROA- Target Price12.00 Perf Year18.95%
Cash/sh0.85 P/C3.64 EPS next 5Y- ROE- 52W Range1.97 - 5.78 Perf YTD43.14%
Dividend- P/FCF- EPS past 5Y24.20% ROI-52.70% 52W High-46.54% Beta2.56
Dividend %- Quick Ratio1.10 Sales past 5Y30.50% Gross Margin29.70% 52W Low56.53% ATR0.22
Employees319 Current Ratio1.70 Sales Q/Q383.90% Oper. Margin- RSI (14)40.61 Volatility5.88% 6.85%
OptionableYes Debt/Eq0.00 EPS Q/Q83.00% Profit Margin- Rel Volume0.51 Prev Close3.12
ShortableYes LT Debt/Eq0.00 EarningsSep 14 Payout- Avg Volume297.46K Price3.09
Recom2.00 SMA20-1.59% SMA50-19.10% SMA200-14.33% Volume151,890 Change-0.96%
Mar-04-16Reiterated FBR Capital Outperform $3.50 → $1
Jul-16-15Initiated Noble Financial Buy $5
Mar-11-14Reiterated MLV & Co Buy $2.50 → $3.50
Sep-27-12Resumed MLV & Co Buy $4.50 → $2
Aug-30-11Initiated JMP Securities Mkt Outperform $5
Sep-19-17 08:05AM  Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition GlobeNewswire
Sep-14-17 06:59PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 14, 2017 Capital Cube
Sep-13-17 01:40PM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017 Capital Cube
Sep-12-17 07:51PM  Edited Transcript of PPHM earnings conference call or presentation 11-Sep-17 8:30pm GMT Thomson Reuters StreetEvents
Sep-11-17 07:54PM  Peregrine reports 1Q loss Associated Press +12.15%
04:05PM  Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments GlobeNewswire
11:00AM  Investor Network: Peregrine Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:05AM  Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices GlobeNewswire
Sep-07-17 08:10AM  Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma GlobeNewswire
Sep-06-17 04:05PM  Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017 GlobeNewswire
Sep-05-17 04:05PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
Aug-30-17 07:21AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Aug-16-17 08:05AM  Avid Bioservices to Exhibit at The Bioprocessing Summit 2017 GlobeNewswire
Aug-14-17 05:10PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : August 14, 2017 Capital Cube
09:01AM  Ronin Trading and SW Investment Management Respond to Recent Announcements by Peregrine Pharmaceuticals PR Newswire
Aug-13-17 10:25AM  Edited Transcript of PPHM earnings conference call or presentation 14-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:42AM  Peregrine Pharmaceuticals laid off one-fifth of its workforce MarketWatch
08:30AM  Peregrine Announces Measures to Reduce Costs, Facilitate Profitability and Strengthen its Operations GlobeNewswire
Aug-03-17 09:15PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : August 4, 2017 Capital Cube -5.40%
Jul-31-17 08:30AM  Peregrine Provides Strategic Update GlobeNewswire
Jul-20-17 08:30AM  Ronin Trading and SW Investment Management Issue Letter to Employees of Peregrine Pharmaceuticals PR Newswire
Jul-19-17 09:49AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 19, 2017 Capital Cube
Jul-18-17 07:20AM  Featured Company News Amgen Submits Regulatory Applications in US, Europe to Include Overall Survival Data in KYPROLIS Label Accesswire
Jul-17-17 08:50AM  Today's Research Reports on Trending Tickers: Peregrine Pharmaceuticals and Westport Fuel Systems Accesswire -6.63%
Jul-14-17 09:51PM  Peregrine reports 4Q loss Associated Press
04:35PM  Peregrine Pharma shares drop after quarterly results fall short MarketWatch
04:14PM  Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments GlobeNewswire
Jul-13-17 06:08PM  Peregrine Pharmaceuticals Issues Statement Regarding Ronin Trading and SW Investment Managements Letter to Stockholders GlobeNewswire +12.94%
08:55AM  Ronin Trading and SW Investment Management Issue Letter to Stockholders of Peregrine Pharmaceuticals PR Newswire
Jul-07-17 04:05PM  Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017 GlobeNewswire
10:25AM  Peregrine Pharmaceuticals Announces Reverse Stock Split GlobeNewswire
Jun-29-17 12:26PM  Top 10 Penny Stocks To Buy in 2017 Insider Monkey
Jun-13-17 08:05AM  Avid Bioservices to Exhibit at the 2017 BIO International Convention Marketwired
Jun-06-17 04:05PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock GlobeNewswire
Jun-05-17 08:05AM  Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017 GlobeNewswire
May-04-17 08:37AM  Implied Volatility Surging for Peregrine Pharmaceuticals (PPHM) Stock Options Zacks
May-02-17 04:30PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : May 2, 2017 Capital Cube
May-01-17 08:00AM  MilliporeSigma's Mobius(R) 2,000-liter Single-use Bioreactors to Expand Avid Bioservices' Manufacturing Capabilities Marketwired +5.59%
Apr-11-17 02:23PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : April 11, 2017 Capital Cube -6.99%
Apr-04-17 08:05AM  Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy GlobeNewswire
08:05AM  Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy
Apr-03-17 08:05AM  Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities GlobeNewswire
Mar-27-17 04:04PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
04:04PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : March 27, 2017
09:30AM  Biotech Industry Continues to Provide Investors with Gains in 2017: Today's Reports on Peregrine Pharmaceuticals and Novavax Accesswire
Mar-23-17 08:05AM  Avid Bioservices Receives Mutliple 2017 CMO Leadership Awards for Quality, Reliability, Capabilties, Expertise and Compatibility Marketwired
07:05AM  Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting GlobeNewswire
Mar-22-17 10:09AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017 Capital Cube
10:09AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017
Mar-17-17 01:04PM  PEREGRINE PHARMACEUTICALS INC Financials
Mar-13-17 04:56PM  Peregrine reports 3Q loss Associated Press +17.17%
04:56PM  Peregrine reports 3Q loss
04:35PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
04:05PM  Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments GlobeNewswire
07:07AM  Q3 2017 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close
Mar-09-17 04:27PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -10.21%
04:05PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
09:30AM  Today's Research Reports on Trending Biotech Tickers: Peregrine Pharmaceuticals and Cara Therapeutics Accesswire
Mar-06-17 08:05AM  Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017 GlobeNewswire
Feb-22-17 08:05AM  Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences GlobeNewswire +10.76%
Feb-10-17 12:43PM  Peregrine Cancer Test Clears Proof of Concept at Investopedia
03:27AM  Can the Rally in Peregrine Pharmaceuticals (PPHM) Shares Continue?
Feb-09-17 08:05AM  Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer GlobeNewswire +10.84%
Jan-24-17 07:14AM  Peregrine Pharmaceuticals (PPHM) Sees Hammer Chart Pattern: Time to Buy?
Jan-20-17 01:48PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : January 20, 2017
Jan-17-17 11:08AM  Heat Biologics to reap benefit of new biotech at bizjournals.com
Jan-04-17 11:26AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : January 4, 2017
Dec-30-16 04:04PM  Plug Power, Innocoll Drop into Fridays 52-Week Low Club
Dec-23-16 01:05PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 23, 2016 +8.34%
Dec-22-16 08:15AM  Blog Coverage Lexicon Pharma's Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary Endpoint Accesswire
Dec-16-16 08:34AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q2, 2017 By the Numbers : December 16, 2016
Dec-13-16 03:59PM  Edited Transcript of PPHM earnings conference call or presentation 12-Dec-16 9:30pm GMT -11.65%
11:43AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 13, 2016
Dec-12-16 04:38PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo -7.55%
04:16PM  Peregrine reports 2Q loss
04:05PM  Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments GlobeNewswire
07:29AM  Is Peregrine Pharmaceuticals (PPHM) A Good Stock To Buy? at Insider Monkey
07:07AM  Q2 2017 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close
Dec-09-16 08:05AM  Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences Marketwired +23.94%
Dec-06-16 04:55PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock GlobeNewswire
Dec-05-16 04:05PM  Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016 GlobeNewswire
Dec-02-16 01:06PM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : December 2, 2016
Nov-14-16 08:05AM  New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals PS-Targeting Antibodies in a Preclinical Melanoma Model GlobeNewswire +8.19%
Oct-24-16 11:54AM  Edited Transcript of PPHM earnings conference call or presentation 8-Sep-16 8:30pm GMT
08:05AM  Preclinical Research Demonstrates Peregrine Pharmaceuticals PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC) GlobeNewswire
Oct-23-16 04:23PM  5 Biotech Penny Stocks Smart Money Is Piling On at Insider Monkey
Oct-17-16 10:34AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 17, 2016
Oct-13-16 04:46PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Oct-12-16 02:26PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Oct-11-16 08:28AM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-10-16 08:05AM  Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 Congress GlobeNewswire -9.15%
Oct-03-16 11:18AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 3, 2016
Sep-27-16 08:05AM  Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC) GlobeNewswire
Sep-26-16 09:55AM  Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q1, 2017 By the Numbers : September 26, 2016
Sep-23-16 10:35AM  ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 23, 2016
Sep-21-16 08:05AM  Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress GlobeNewswire +11.29%
Sep-09-16 10:00PM  Peregrine Results Reaffirm On-Track Revenue Projection (PPHM) at Investopedia -6.31%
Sep-08-16 04:30PM  Peregrine reports 1Q loss
04:18PM  PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate is bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy, and support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; and Lonza Biologics, as well as collaboration agreement with National Comprehensive Cancer Network, AstraZeneca PLC, and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.